<PAGE>
                                                                   EXHIBIT 10.14


*Certain confidential information contained in this document, marked by
brackets, has been omitted and filed with the Securities and Exchange Commission
pursuant to Rule 406 of the Securities Act of 1933, as amended.

CORIXA CORPORATION
1124 Columbia Street, Suite 200
Seattle WA 98104, USA
ATTENTION : STEVE GILLIS

RE:  CLARIFICATIONS SOUGHT IN CONNECTION WITH THE MULTI-FIELD VACCINE
     DISCOVERY COLLABORATION AND LICENSE AGREEMENT, ENTERED INTO SEPTEMBER 1,
     1998, BETWEEN CORIXA CORPORATION("CORIXA") AND SMITHKLINE BEECHAM PLC
     ("GSK") AS AMENDED (THE "AGREEMENT")

Dear Steve:

As we discussed at the Collaboration Steering Committee meeting held June 12,
2001, Corixa and GSK wish to confirm hereby their understanding regarding the
maintenance of GSK's exclusive rights in Fields with respect to which GSK begins
Clinical R&D and the definition of "Therapeutic Drug Monitoring" or "TDM".
Please note that capitalized terms not otherwise defined in this letter shall
have the meanings ascribed to them in the Agreement.

Following is our understanding of the terms and conditions under which GSK
maintains the exclusive rights and licenses in a particular Field where GSK
begins Clinical R&D with a particular Active Immune Response Product or Passive
Immune Transfer Product prior to the lapse of the Intended Clinical Delay:

1.   If GSK begins Clinical R&D with an Active Immune Response Product or
     Passive Immune Transfer Product containing at least one (1) [*], subject to
     Corixa's right to terminate the Agreement as provided for in Section 17
     thereof, GSK shall be deemed to have begun Clinical R&D in the [*] and all
     rights and licenses granted to GSK pursuant to Section 5 with respect to
     the [*] shall be valid in accordance with the terms of the Agreement for so
     long as GSK is engaged in Clinical R&D, further clinical development or
     commercialisation of at least one (1) Active Immune Response Product or
     Passive Immune Transfer Product in the [*], as per the Agreement.

2.   For any field other than [*], if GSK begins Clinical R&D with an Active
     Immune Response Product or Passive Immune Transfer Product containing a
     Corixa Antigen and/or R&D Program Antigen, other than a [*], which has been
     discovered or identified within the framework of an R&D Program in a
     particular Field ("Field 1") and has been selected as a Viable Clinical
     Development Candidate for human clinical studies conducted in another Field
     ("Field 2"), subject to Corixa's right to terminate the Agreement as
     provided for in Section 17 thereof, GSK shall be deemed to have begun
     Clinical R&D in both Field 1 and Field 2 and the rights and licenses
     granted to GSK pursuant to Section 5 with respect to both Fields shall be
     valid in accordance with the terms of the Agreement for so long as GSK is
     engaged in Clinical R&D, further clinical development or commercialisation
     of at least one (1) Active Immune Response Product or Passive Immune
     Transfer Product in Field 1 or in Field 2, as per the Agreement.

----------
*Confidential Treatment Requested.

<PAGE>

We agreed to clarify the definition of "Therapeutic Drug Monitoring" or "TDM"
contained in Section 1 (xxxxx) of the Agreement to read as follows :

3.   "Therapeutic Drug Monitoring" (or "TDM") shall mean the use of Antigen(s)
     solely for the purpose of [*] for an Active Immune Response Product and/or
     a Passive Immune Transfer Product that incorporates or is based on such
     Antigen(s), or for [*] such Active Immune Response Product and/or Passive
     Immune Transfer Product, as applicable, either during the [*] of such
     Active Immune Response Product and/or Passive Immune Transfer Product, as
     applicable, or following [*] thereof.

     For further clarification, a TDM Product can only be [*].


If Corixa agrees to the foregoing, please have the enclosed duplicate original
of this letter executed as indicated below and returned to my attention.

Best regards,


/s/ Jean Stephenne

Jean Stephenne
Attorney-in-Fact
SMITHKLINE BEECHAM PLC


AGREED TO AND ACCEPTED BY:

CORIXA CORPORATION


/s/ Steven Gillis
---------------------------------------
Steven Gillis
Chairman and Chief Executive Officer

--------
* Confidential Treatment Requested.